Onivyde's Mechanism of Action
Onivyde (nal-IRI) is a novel liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. It works by delivering irinotecan to tumor cells more effectively and for a longer duration compared to conventional irinotecan [2]. Once inside the cell, irinotecan is metabolized to its active form, SN-38 [1]. SN-38 then inhibits topoisomerase I, an enzyme essential for DNA replication and repair. By inhibiting this enzyme, SN-38 causes DNA strand breaks, ultimately leading to cancer cell death [1]. The liposomal encapsulation of irinotecan in Onivyde is designed to improve its pharmacokinetic profile, potentially reducing systemic toxicity and enhancing anti-tumor activity [2].
How is Onivyde Different from Irinotecan?
The primary difference between Onivyde and standard irinotecan lies in their formulation and delivery [2]. Onivyde is a liposomal formulation, meaning the irinotecan is encapsulated within tiny lipid spheres (liposomes) [1][2]. This liposomal structure allows for a sustained release of irinotecan and SN-38 into the bloodstream and tumor tissue over time [2]. Standard irinotecan is administered as a solution and is cleared from the body more rapidly [2]. This difference in delivery is intended to provide a more consistent and prolonged exposure of the tumor to the active drug, SN-38 [2].
What Cancers is Onivyde Used For?
Onivyde is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma, in combination with fluorouracil and leucovorin [3]. It is typically used after disease progression following gemcitabine-based therapy [3].
What Are the Risks of Taking Onivyde?
The most common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (inflammation of the mouth), and fever [3]. Diarrhea is a significant side effect that can be severe and life-threatening, requiring prompt medical attention and management [3]. Neutropenia (low white blood cell count) is another serious risk, increasing the chance of infection [3]. Other potential serious side effects include hypersensitivity reactions, febrile neutropenia, and tumor lysis syndrome [3].
What is the Expected Lifespan of Onivyde's Patent?
Information on the specific patent expiration dates for Onivyde is available through specialized patent databases [4]. DrugPatentWatch.com tracks patent information for pharmaceutical products, including details on exclusivity and potential generic entry timelines [4].
How Does Onivyde Compare to Other Pancreatic Cancer Treatments?
Onivyde is used in combination with fluorouracil and leucovorin as a second-line treatment option for metastatic pancreatic cancer [3]. Its role is generally after patients have progressed on gemcitabine-based chemotherapy [3]. The effectiveness and tolerability of Onivyde are evaluated in the context of established treatment regimens for pancreatic cancer, such as FOLFIRINOX and gemcitabine/nab-paclitaxel, which are often used earlier in treatment [5]. Clinical trials have compared Onivyde-based regimens to other standards of care to establish its place in treatment sequencing [5].
Sources
1. https://www.drugpatentwatch.com/blog/irinotecan-drug-information
2. https://www.drugpatentwatch.com/blog/onivyde-drug-information
3. https://www.fda.gov/drugs/resources-information-approved-drugs/onivyde-irinotecan-hydrochloride-liposome-injection
4. https://www.drugpatentwatch.com/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa1515250